A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

NCT07336953 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: GnP
RADIATION: SBRT
DRUG: Serplulimab

Sponsor

West China Hospital